Phytotherapeutic management of polycystic ovary syndrome: Role of aerial parts of wood betony (Stachys lavandulifolia)

Phytotherapy Research

Volumn 27, Issue 11, 2013, Pages 1708-1713

  Jalilian, Nasrin ^a   Modarresi, Masoud ^b   Rezaie, Mansour ^a   Ghaderi, Leila ^a   Bozorgmanesh, Mohammadreza ^c  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

medroxyprogesterone acetate; polycystic ovary syndrome; wood betony

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; MEDROXYPROGESTERONE ACETATE; PLANT EXTRACT; STACHYS LAVANDULIFOLIA EXTRACT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; OLIGOMENORRHEA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PHYTOCHEMISTRY; RANDOMIZED CONTROLLED TRIAL; STACHYS; STACHYS LAVANDULIFOLIA; TREATMENT DURATION; UTERUS BLEEDING; WOOD;

STACHYS COCCINEA; STACHYS LAVANDULIFOLIA;

MEDROXYPROGESTERONE ACETATE; POLYCYSTIC OVARY SYNDROME; WOOD BETONY;

ADOLESCENT; ADULT; FEMALE; HUMANS; LINEAR MODELS; MEDROXYPROGESTERONE ACETATE; PHYTOTHERAPY; PLANT COMPONENTS, AERIAL; POLYCYSTIC OVARY SYNDROME; STACHYS; UTERINE HEMORRHAGE; YOUNG ADULT;

EID: 84886290944     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4921     Document Type: Article

References (35)

1. Akdoǧan M, Tamer MN, Cüre E, Cüre MC, Köroǧlu BK, Delibaş N,. 2007. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytother Res 21: 444-447.
2. Amatayakul K, Sivasomboon B, Thanangkul O,. 1980. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22: 605-622.
3. Bonny AE, Britto MT, Huang B, Succop P, Slap GB,. 2004. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol 17: 109-115.
4. Breinholt V, Hossaini A, Svendsen GW, Brouwer C, Nielsen S,. 2000. Estrogenic activity of flavonoids in mice. The importance of estrogen receptor distribution, metabolism and bioavailability. Food Chem Toxicol 38: 555-564.
5. Butterweck V, Hegger M, Winterhoff H,. 2004. Flavonoids of St. John's Wort reduce HPA axis function in the rat. Planta Med 70: 1008-1011.
6. Cook RJ, Sackett DL,. 1995. The number needed to treat: a clinically useful measure of treatment effect. BMJ 310: 452.
7. Diaz FJ, Luo W, Wiltbank MC,. 2011. Effect of Decreasing Intraluteal Progesterone on Sensitivity of the Early Porcine Corpus Luteum to the Luteolytic Actions of Prostaglandin F2alpha. Biol Reprod 84: 26-33.
8. Ely JW, Kennedy CM, Clark EC, Bowdler NC,. 2006. Abnormal Uterine Bleeding: A Management Algorithm. J Am Board Fam Med 19: 590-602.
9. Harrell FE,. 2001. Regression modeling strategies. Springer: New York.
10. Harrell FE, Jr., Lee KL, Mark DB,. 1996. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387.
11. Hertog MGL, Hollman PCH, Katan MB,. 1992. Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in the Netherlands. J Agric Food Chem 40: 2379-2383.
12. Jones G, Hall J, Balen A, Ledger W,. 2008. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum Reprod Update 14: 15-25.
13. LaGow B,. 2004. PDR for herbal medicines. Thomson PDR: Montvale, New Jersey.
14. Le Bail J, Varnat F, Nicolas J, Habrioux G,. 1998. Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett 130: 209-216.
15. Mangan SA, Larsen PG, Hudson S,. 2002. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 15: 79-82.
16. Marshall K,. 2001. Polycystic ovary syndrome: clinical considerations. Alternat Med Rev 6: 272.
17. Mayo JL,. 1997. A healthy menstrual cycle. Clin Nutr Insights 5: 1-8.
18. Monji F, Tehrani HH, Halvaei Z, Bidgoli SA,. 2011. Acute and Subchronic Toxicity Assessment of the Hydroalcoholic Extract of Stachys lavandulifolia in Mice. Acta Med Iran 49: 769-775.
19. Nahid K, Fariborz M, Ataolah G, Solokian S,. 2009. The effect of an Iranian herbal drug on primary dysmenorrhea: a clinical controlled trial. J Midwifery Womens Health 54: 401-404.
20. Noguchi M, Ikarashi Y, Yuzurihara M, et al,. 2003. Effects of the Japanese herbal medicine Keishi-bukuryo-gan and 17beta-estradiol on calcitonin gene-related peptide-induced elevation of skin temperature in ovariectomized rats. J Endocrinol 176: 359-366.
21. Prajapati ND, Kumar U,. 2003. Agro's dictionary of medicinal plants. Agrobios: India.
22. Rabbani M, Sajjadi S, Zarei H,. 2003. Anxiolytic effects of Stachys lavandulifolia Vahl on the elevated plus-maze model of anxiety in mice. J Ethnopharmacol 89: 271-276.
23. Resnik S,. 1967. MElasma induced by oral contraceptive drugs. JAMA 199: 601-605.
24. Rotterdam E,. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19.
25. Russo E,. 2002. Cannabis treatments in obstetrics and gynecology: A historical review. J Cannabis Therapeut 2: 5-35.
26. Shobeiri SF, Sharei S, Heidari A, Kianbakht S,. 2009. Portulaca oleracea L. in the treatment of patients with abnormal uterine bleeding: a pilot clinical trial. Phytother Res 23: 1411-1414.
27. Speroff L, Fritz MA,. 2005. Clinical gynecologic endocrinology and infertility. Lippincott Williams & wilkins: Philadelphia, USA.
28. Steyerberg EW,. 2009. Clinical prediction models: a practical approach to development, validation, and updating. Springer: Londin, UK.
29. Steyerberg EW, Eijkemans MJ, Habbema JD,. 1999. Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52: 935-942.
30. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD,. 2000. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19: 1059-1079.
31. Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B,. 2012. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest 42: 216-228.
32. Wang H,. 2006. The role of metformin in the treatment of polycystic ovary syndrome (PCOS). Chang Gung Med J 29: 445.
33. Wang JG, Anderson RA, Graham GM, et al,. 2007. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril 88: 240-243.
34. Webber L, Stubbs S, Stark J, et al,. 2003. Formation and early development of follicles in the polycystic ovary. Lancet 362: 1017-1021.
35. Zafari Zangeneh F, Minaee B, Amirzargar A, Ahangarpour A, Mousavizadeh K,. 2010. Effects of chamomile extract on biochemical and clinical parameters in a rat model of polycystic ovary syndrome. J Reprod Infert 11: 169-174.